4914 related articles for article (PubMed ID: 2916650)
1. Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.
Garin-Chesa P; Beresford HR; Carrato-Mena A; Oettgen HF; Old LJ; Melamed MR; Rettig WJ
Am J Pathol; 1989 Feb; 134(2):295-303. PubMed ID: 2916650
[TBL] [Abstract][Full Text] [Related]
2. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
3. Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals.
Rettig WJ; Real FX; Spengler BA; Biedler JL; Old LJ
Science; 1986 Mar; 231(4743):1281-4. PubMed ID: 3633135
[TBL] [Abstract][Full Text] [Related]
4. The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface.
Garrigues HJ; Lark MW; Lara S; Hellström I; Hellström KE; Wight TN
J Cell Biol; 1986 Nov; 103(5):1699-710. PubMed ID: 2430975
[TBL] [Abstract][Full Text] [Related]
5. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
Carrel S; Schreyer M; Gross N; Zografos L
Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
[TBL] [Abstract][Full Text] [Related]
6. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
7. Assignment of the human aggrecan gene AGC1 to 15q25-->q26.2 by in situ hybridization.
Just W; Klett C; Vetter U; Vogel W
Hum Genet; 1993 Nov; 92(5):516-8. PubMed ID: 8244345
[TBL] [Abstract][Full Text] [Related]
8. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
9. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
10. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
11. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
12. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.
Bernhard H; Roth S; Bauerschmitz J; Meyer zum Büschenfelde KH; Dippold W
Int J Cancer; 1992 Jun; 51(4):568-72. PubMed ID: 1376299
[TBL] [Abstract][Full Text] [Related]
13. Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells.
Harper JR; Bumol TF; Reisfeld RA
J Immunol; 1984 Apr; 132(4):2096-104. PubMed ID: 6199423
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
Kageshita T; Nakamura T; Yamada M; Kuriya N; Arao T; Ferrone S
Cancer Res; 1991 Mar; 51(6):1726-32. PubMed ID: 1671829
[TBL] [Abstract][Full Text] [Related]
15. [Biochemistry of melanoma-associated ganglioside antigens].
Hirabayashi Y; Higashi H; Taniguchi M
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):834-40. PubMed ID: 2421644
[TBL] [Abstract][Full Text] [Related]
16. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
[TBL] [Abstract][Full Text] [Related]
17. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.
Dippold WG; Lloyd KO; Li LT; Ikeda H; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6114-8. PubMed ID: 6934537
[TBL] [Abstract][Full Text] [Related]
18. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
19. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.
Hamilton WB; Helling F; Lloyd KO; Livingston PO
Int J Cancer; 1993 Feb; 53(4):566-73. PubMed ID: 8436430
[TBL] [Abstract][Full Text] [Related]
20. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
Ravindranath MH; Morton DL; Irie RF
Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
